Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $28.00 | Outperform | RBC Capital Mkts |
| 1/7/2025 | $33.00 | Buy | Citigroup |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 8/28/2024 | $15.00 | Buy | Jefferies |
| 1/22/2024 | $35.00 | Overweight | JP Morgan |
| 11/2/2023 | $20.00 | Buy | Mizuho |
| 4/21/2023 | $33.00 | Outperform | Robert W. Baird |
| 7/7/2022 | $21.00 | Buy | Chardan Capital Markets |
8-K - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)
144 - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
8-K - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)
RBC Capital Mkts initiated coverage of EyePoint Pharmaceuticals with a rating of Outperform and set a new price target of $28.00
Citigroup initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $33.00
Scotiabank initiated coverage of EyePoint Pharmaceuticals with a rating of Sector Outperform
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)
– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – – On track to report topline 56-week data for LUGANO in mid-2026 with LUCIA data to closely follow – WATERTOWN, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the independent Data Safety Monitoring Committee (DSMC) completed its second scheduled review of the Company's ongoing pivotal Phase 3 program e
WATERTOWN, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 31,000 shares of EyePoint common stock to seven new employees. The stock options were granted on November 14, 2025. The grants were approved by the Compensation Committee and made as an
– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME program consisting of two identical non-inferiority trials, COMO and CAPRI; first patient dosing anticipated in Q1 2026 – – Announced preclinical data demonstrating DURAVYU's potential as a multi-target treatment inhibiting both VEGF-mediated vascular permeability and IL-6 mediated inflammation, key contributors to wet AMD and DME – – $172.5 million oversubscribed equity financing fully funds DME pivotal program and extends cash runway into Q4 2027 – WATERTOWN, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- EyePo
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. "I am pleased to welcome Dr. Sanders to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint. "Scientific and medical leadership underpin our mission to develop innovative therapeutics for patients with serious retinal diseases, and as a prominent leader in the retina community, Dr. San
WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors. "I am honored to welcome Fred Hassan to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint Pharmaceuticals. "He joins at an important time for the Company as we approach first patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and as we prepare for future
- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board – - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O, F.A.R.V.O join in advance of global Phase 3 clinical trials for EYP-1901(DURAVYU) in wet AMD – - Company on track to initiate the first Phase 3 pivotal trial (LUGANO) for DURYVU in wet AMD in 2H 2024 - WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists
WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 5, 2025 to report its third quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/fgkir3sg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharm
– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO on track for readout in mid-2026 with LUCIA topline data to closely follow – – Northbridge, MA commercial manufacturing facility on line with DURAVYU registration batches underway – – $256 million of cash, cash equivalents and marketable securities as of June 30, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials – WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuti
WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register-conf.media-server.com/register/BI2f02d8b4966b40da83f2ef4135b2ba78. A live audio webcast of the event can be accessed via the Investors section of the
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)
SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)